Insulin-like growth factor-I receptor signaling and resistance to transtuzumab (Herceptin)

Journal of the National Cancer Institute

Volumn 93, Issue 24, 2001, Pages 1852-1857

  Lu, Yuhong ^a   Zi, Xiaolin ^a   Zhao, Yunhua ^a   Mascarenhas, Desmond ^b   Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Protigen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035915421     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.24.1852     Document Type: Article

References (45)

1. Untangling the ErbB signalling network
2. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function
3. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
4. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2
5. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling
6. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Molecular targets for breast cancer therapy and prevention
9. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
10. Receptor blockade with monoclonal antibodies as anti-cancer therapy
11. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
12. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
13. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
14. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
15. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory treatment
16. Clinical trials of Herceptin (trastuzumab)
17. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2
18. From the molecule to the clinic-inhibiting HER2 to treat breast cancer
19. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
20. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
21. Insulin-like growth factor-I and new opportunities for cancer prevention
22. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk
23. Insulin-like growth factor physiology and cancer risk
24. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
25. Role of the insulin-like growth factor family in cancer development and progression
26. Insulin-like growth factors and prostate cancer
27. The role of the insulin-like growth factor I receptor in transformation and apoptosis
28. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
29. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR)
30. Regulation of survival signals from the insulin-like growth factor-I receptor
31. Molecular and cellular aspects of the insulin-like growth factor I receptor
32. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
33. The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity. Evidence from receptor chimeras
34. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells
35. The insulin-like growth factor-binding protein (IGFBP) super-family
36. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms
37. WAF1/Cip1
38. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components
39. Proliferation, cell cycle and apoptosis in cancer
40. Oncogenic kinase signalling
41. Mammalian MAP kinase signalling cascades
42. Cell signaling by receptor tyrosine kinases
43. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes
44. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission
45. Signaling networks: The origins of cellular multitasking